Tuesday, 27 September 2022

Lecanemab phase 3 Clarity AD study in early Alzheimer's disease meets primary and all key secondary endpoints with high statistical significance

1

https://worldnewsguru.us/business/lecanemab-phase-3-clarity-ad-study-in-early-alzheimers-disease-meets-primary-and-all-key-secondary-endpoints-with-high-statistical-significance/400220/

No comments:

Post a Comment